TY - JOUR
T1 - Poor prognosis of nucleophosmin overexpression in solid tumors
T2 - A meta-analysis
AU - Chen, Siying
AU - He, Hairong
AU - Wang, Yan
AU - Liu, Leichao
AU - Liu, Yang
AU - You, Haisheng
AU - Dong, Yalin
AU - Lyu, Jun
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/8/20
Y1 - 2018/8/20
N2 - Background: Nucleophosmin is a non-ribosomal nucleolar phosphoprotein that is found primarily in the nucleolus region of cell nucleus, plays multiple important roles in tumor processes. Accumulated previous studies have reported a potential value of NPM acted as a biomarker for prognosis in various solid tumors, but the results were more inconsistency. We performed this meta-analysis to precisely evaluate the prognostic significance of NPM in solid tumors. Methods: Clinical data were collected from a comprehensive literature search in PubMed, Web of Science, Embase, and China National Knowledge Infrastructure databases (up to October, 2017). A total of 11 studied with 997 patients were used to assess the association of NPM expression and patients' overall survival (OS). The hazard ratio (HR) or odds ratio (OR) with its 95% confidence intervals (CI) were calculated to estimate the effect. Results: The pooled results indicated that higher expression of NPM was observably correlated with poor OS in solid tumor (HR=1.85, 95% CI: 1.44-2.38, P<0.001). Furthermore, high expression of NPM was associated with some phenotypes of tumor aggressiveness, such as tumor stage (4 studies, III/IV vs. I/II, OR=5.21, 95% CI: 2.72-9.56, P<0.001), differentiation grade (poor vs. well/moderate, OR=1.82, 95% CI: 1.01-3.27, P=0.046). Conclusion: This meta-analysis indicated that NPM may act as a valuable prognosis biomarker and a potential therapeutic target in human solid tumors.
AB - Background: Nucleophosmin is a non-ribosomal nucleolar phosphoprotein that is found primarily in the nucleolus region of cell nucleus, plays multiple important roles in tumor processes. Accumulated previous studies have reported a potential value of NPM acted as a biomarker for prognosis in various solid tumors, but the results were more inconsistency. We performed this meta-analysis to precisely evaluate the prognostic significance of NPM in solid tumors. Methods: Clinical data were collected from a comprehensive literature search in PubMed, Web of Science, Embase, and China National Knowledge Infrastructure databases (up to October, 2017). A total of 11 studied with 997 patients were used to assess the association of NPM expression and patients' overall survival (OS). The hazard ratio (HR) or odds ratio (OR) with its 95% confidence intervals (CI) were calculated to estimate the effect. Results: The pooled results indicated that higher expression of NPM was observably correlated with poor OS in solid tumor (HR=1.85, 95% CI: 1.44-2.38, P<0.001). Furthermore, high expression of NPM was associated with some phenotypes of tumor aggressiveness, such as tumor stage (4 studies, III/IV vs. I/II, OR=5.21, 95% CI: 2.72-9.56, P<0.001), differentiation grade (poor vs. well/moderate, OR=1.82, 95% CI: 1.01-3.27, P=0.046). Conclusion: This meta-analysis indicated that NPM may act as a valuable prognosis biomarker and a potential therapeutic target in human solid tumors.
KW - Meta-analysis
KW - NPM
KW - Prognosis
KW - Sold tumors
UR - https://www.scopus.com/pages/publications/85052078260
U2 - 10.1186/s12885-018-4718-6
DO - 10.1186/s12885-018-4718-6
M3 - 文章
C2 - 30126359
AN - SCOPUS:85052078260
SN - 1471-2407
VL - 18
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 838
ER -
